Announcements Trials
Browse Landscape

Status

Completed 851Terminated 244Recruiting 223Unknown 213Active not recruiting 111Withdrawn 71Not yet recruiting 52Enrolling by invitation 6Suspended 5Available 3Approved for marketing 3No longer available 2

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Interventions

selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Available × Lymphoma, Large B-Cell, Diffuse × Clear all
NCT07215832 2026-03-02

KEAP

Karyopharm Therapeutics Inc

Available
GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Regeneron Pharmaceuticals

Available
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04400591 2025-12-11

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Juno Therapeutics, a Subsidiary of Celgene

Available
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡